GlassScriptPhysician profile
Robert L Parker
NPI 1194715839
$2,279.62
in general payments reported to CMS, 2019-2025
34 companies · $1,651 in 2025
The $1,651 reported for 2025 was more than what 93% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $288 · 2020: $51.58 · 2021: $47.99 · 2022: $126 · 2023: $41.21 · 2024: $73.05 · 2025: $1,651.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $990 · Food and Beverage: $775.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $990.24 |
| Food and Beverage | $775.16 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $1,539.89 | 2019-2025 | |
| Abbvie INC. | $143.38 | 2019-2025 | |
| Pfizer INC. | $109.74 | 2019-2023 | |
| Daiichi Sankyo INC. | $78.03 | 2019-2020 | |
| Therapeuticsmd, INC. | $61.93 | 2019-2022 | |
| Astellas Pharma US INC | $43.16 | 2022-2025 | Veozah |
| Mayne Pharma Commercial LLC | $32.37 | 2024 | |
| Mission Pharmacal Company | $26.57 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $26.04 | 2025 | Trintellix |
| Amag Pharmaceuticals, INC. | $23.75 | 2019 | |
| Biogen, INC. | $22.31 | 2024 | Zurzuvae |
| Exeltis, USA INC. | $22.21 | 2025 | Slynd |
| Novo Nordisk INC | $20.87 | 2023 | Wegovy |
| Myovant Sciences INC. | $18.99 | 2022 | |
| Sumitomo Pharma America, INC. | $18.37 | 2024 | Gemtesa |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Evofem Biosciences, INC. | $17.15 | 2021 | |
| Roche Diagnostics Corporation | $16.98 | 2019 | |
| Shield Therapeutics INC | $15.51 | 2025 | |
| Vertex Pharmaceuticals Incorporated | $14.81 | 2025 | |
| Merck Sharp & Dohme LLC | $14.61 | 2019 | |
| Vertical Pharmaceuticals, LLC | $12.95 | 2019 |
13 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$5.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Parker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.